Hyperpolarized 129 Xenon Gas
DrugHyperpolarized xenon gas is inhaled during MRI to evaluate lung ventilation and gas exchange.
NCT Number: NCT07821398
This study aims to evaluate a noninvasive magnetic resonance imaging technique using hyperpolarized xenon gas to measure lung function in adults with interstitial lung disease, pulmonary hypertension, and systemic sclerosis. Researchers will assess whether MRI measurements correlate with clinical measures of lung and vascular function.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 2
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hyperpolarized xenon gas is inhaled during MRI to evaluate lung ventilation and gas exchange.
Time frame: Single study visit, Day 1
Sensitivity of pre-specified 129Xe MRI biomarkers for identifying pre-capillary pulmonary hypertension in participants with systemic sclerosis, using right-heart catheterization as the reference standard.
Time frame: Single study visit, Day 1
Specificity of pre-specified 129Xe MRI biomarkers for identifying pre-capillary pulmonary hypertension in participants with systemic sclerosis, using right-heart catheterization as the reference standard.
Time frame: Single study visit, Day 1
Percentage of lung volume exhibiting abnormal regional RBC oscillation amplitude as measured by hyperpolarized 129Xe MRI.
Time frame: Single study visit, Day 1
Mean frequency difference between the center of the RBC resonance and the alveolar gas resonance.
Bastiaan Driehuys
Other
Harmonized Hyperpolarized 129Xe MRI for Noninvasive Assessment of Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis (ILD-PH/SSc)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06416163
Cardiovascular Diseases, Fibrosis
London, United Kingdom
View Trial DetailsNCT07816185
Cardiovascular Diseases, Fibrosis
Kissimmee, Florida, United States
View Trial DetailsNCT06635850
Cardiovascular Diseases, Fibrosis
Phoenix, Arizona, United States
View Trial DetailsNCT06388421
Cardiovascular Diseases, Hypertension
Birmingham, Alabama, United States
View Trial Details